Modus Therapeutics Holding
Modus Therapeutics Holding is a Swedish biotechnology group focused on developing sevuparin, a patented low-anticoagulant heparinoid drug candidate. The company operates through its wholly owned subsidiary Modus Therapeutics AB and is centered on clinical development for severe diseases with high unmet medical need.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueClinical and preclinical development of the sevuparin drug candidate across target indications.
Externally partnered studies and scientific collaborations supporting indication expansion.
Customers
Modus does not sell a commercialized drug to end customers; its value creation is directed toward future partners, licensors, and development collaborators. The main counterparties are research institutions, clinical study sites, and potential pharmaceutical partners that can advance or commercialize sevuparin in specific indications.
Potential partners that may license, co-develop, or commercialize sevuparin after clinical value is established.
Hospitals and investigators that enroll patients and generate trial data for CKD-anemia and other programs.
Universities and research groups that support mechanism, indication, and translational studies.
Organizations that may fund selected programs such as severe malaria research.
Strategy
Modus is focused on building clinical evidence for sevuparin in CKD with anemia, then using that data to support partnering with established commercial players. A second strategic pillar is selective expansion into other severe diseases, especially where external funding or collaboration can reduce development burden.
This is the core value driver for sevuparin and the main basis for future partnering.
The company aims to realize value through collaborations with players that have commercial reach.
Broader indication work can increase the asset's value while limiting capital intensity through external support.
Geography
Modus is headquartered in Stockholm, Sweden, and its operating structure is centered in Sweden through the parent company and wholly owned subsidiary. Its clinical and collaboration footprint extends into Europe, including study sites in Italy and partnerships with international research institutions for selected programs.
Risks
The business is exposed to clinical development risk because sevuparin remains dependent on trial outcomes, patient recruitment, and regulatory progress. It also faces financing risk typical of development-stage biotech companies, since continued operations depend on access to capital and the ability to fund long-duration research programs.
- Drug development failureImpact: CriticalLikelihood: Medium
Sevuparin's value depends on clinical efficacy, safety, and regulatory acceptance.
Exposure: CKD-anemia and other severe indications
- Financing riskImpact: HighLikelihood: High
The company is research-intensive and relies on external capital to fund operations.
Exposure: Ongoing clinical programs and corporate overhead
- Trial execution riskImpact: HighLikelihood: Medium
Recruitment, site performance, and data generation affect timelines and study quality.
Exposure: Phase IIa CKD study and collaboration programs
- Capital market and macro riskImpact: MediumLikelihood: High
Interest rates, inflation, and geopolitical uncertainty can weaken financing conditions.
Exposure: Equity issuance and investor appetite
Accounting
Judgemental itemsThe company states that its development work does not meet all capitalization criteria, so costs are expensed and affect operating loss.
Impact: Higher current-period expenses and no intangible asset build-up
Parent-company turnover consists of invoicing the wholly owned subsidiary, which is important for understanding reported revenue.
Impact: Revenue is internal to the group structure and not external sales
Rights issues and warrants can materially change share count and equity balances.
Impact: Dilution, cash proceeds, and potential future equity issuance
The company’s ability to continue depends on successful capital raising and clinical progress.
Impact: Material uncertainty disclosure and valuation sensitivity
Similar listed companies
Publicly listed companies with a comparable business focus.
Swedish Orphan Biovitrum
SOBI · Health Care
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Medicus Pharma Ltd.
MDCXW · Pharmaceutical Preparations
Sedana Medical
SEDANA · Health Care
Sedana Medical is a Swedish company based in Danderyd that specializes in developing, manufacturing, and selling medical devices and pharmaceuticals.
SeaStar Medical Holding Corp
ICUCW · Surgical & Medical Instruments & Apparatus
SeaStar Medical Holding Corp is a U.S.-based medical device company focused on therapies that treat acute and chronic kidney injury through selective cytopheretic devices.
Oculis Holding AG
OCS · Pharmaceutical Preparations
Oculis Holding AG is a Switzerland-based biopharmaceutical company focused on therapies for neuro-ophthalmology and ophthalmology.
Last updated: 24/09/2026